EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FT-4202, a selective pyruvate kinase R activator for sickle cell disease

Anna Ericsson, David J Richard, Erik Wilker, David R Lancia, Shawn Fessler, Paul Troccolo, Xiaozhang Zheng, Angela Toms, Christopher Dinsmore, Lili Yao, Frans A Kuypers, Sandra Larkin und 5 weitere

Experimental Hematology · 2025

DOI: 10.1016/j.exphem.2024.104673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Hematology, 2025. Verfasst von Anna Ericsson und 16 weiteren Autor:innen. Beteiligte Einrichtung: Forma Therapeutics, Inc., Watertown, MA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Pyruvate Kinase, Enzyme Activators. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anemia in patients with sickle cell disease (SCD) increases 2,3-diphosphoglycerate (2,3-DPG), decreasing hemoglobin-oxygen (HbO2) affinity to improve oxygen offloading and promote hemoglobin polymerization (sickling) of red blood cells (RBCs). We report the discovery of FT-4202, an investigational, selective pyruvate kinase type-R (PKR) activator with a multimodal mechanism of action and potential to increase ATP and decrease 2,3-DPG, resulting in increased HbO2 affinity, decreased Hb polymerization, and improved RBC health. FT-4202 was identified via structure-enabled lead optimization medicinal chemistry using X-ray crystallography, molecular modeling, and thermal shift assays. FT-4202, an allosteric PKR activator, stabilizes the tetrameric enzyme and increases PKR activity in human and mouse RBCs in vitro. Seven-day oral administration of FT-4202 in Berkeley SCD mice reduced 2,3-DPG, increased HbO2 affinity, and reduced RBC sickling versus control. There were no adverse in vitro safety findings. FT-4202 offers a therapeutic opportunity to modify the course of SCD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellPyruvate KinaseEnzyme ActivatorsAnimalsHumansMiceErythrocytes2,3-DiphosphoglycerateModels, Molecular

Substanzen

Pyruvate Kinase2,3-DiphosphoglyceratePKLR protein, humanEnzyme Activators

Autor:innen und Institutionen

  • Forma Therapeutics, Inc., Watertown, MA.
  • University of California San Francisco, Oakland, CA.
  • Novo Nordisk, Watertown, MA. Electronic address: sygx@novonordisk.com.

Zitieren

APA

Ericsson, A., Richard, D. J., Wilker, E., Lancia, D. R., Fessler, S., Troccolo, P., Zheng, X., Toms, A., Dinsmore, C., Yao, L., Kuypers, F. A., Larkin, S., Marcotte, D., Fulzele, K., Ribadeneira, M., Guichard, S. M., & Marshall, G. (2025). FT-4202, a selective pyruvate kinase R activator for sickle cell disease. Experimental Hematology. https://doi.org/10.1016/j.exphem.2024.104673

Vancouver

Ericsson A, Richard DJ, Wilker E, Lancia DR, Fessler S, Troccolo P, et al. FT-4202, a selective pyruvate kinase R activator for sickle cell disease. Experimental Hematology. 2025. doi:10.1016/j.exphem.2024.104673

BibTeX
@article{Ericsson2025,
  author = {Ericsson, Anna and Richard, David J and Wilker, Erik and Lancia, David R and Fessler, Shawn and Troccolo, Paul and Zheng, Xiaozhang and Toms, Angela and Dinsmore, Christopher and Yao, Lili and Kuypers, Frans A and Larkin, Sandra and Marcotte, Douglas and Fulzele, Keertik and Ribadeneira, Maria and Guichard, Sylvie M and Marshall, Gary},
  title = {FT-4202, a selective pyruvate kinase R activator for sickle cell disease},
  journal = {Experimental Hematology},
  year = {2025},
  doi = {10.1016/j.exphem.2024.104673}
}
Kostenlos starten →